JNJ-42915925 / J&J, Novartis - LARVOL DELTA

Major role of lactate dehydrogenase D-LDH1 for the synthesis of lactic acid in Fructobacillus tropaeoli CRL 2034. (PubMed, Appl Microbiol Biotechnol) - "The growth kinetic parameters were affected only in CRL2034 ldh1::pRV300 cells, this mutant showing the lowest total lactic acid production (4.50 ± 0.15 versus 6.36 ± 0.67 g/L of wild-type strain), with a D/L ratio of 7.1:2.9...•Gene ldh1 plays the major role in lactic acid production by strain CRL 2034. •Fructobacillus D-LDH phylogeny was consistent to phylogenetic evolution."

Journal

Provention Bio reports second quarter 2018 financial results and provides business update (PRNewswire) - "PRV-300 is currently in a...Phase 1b clinical trial – the PULSE (Provention ULcerative Colitis Stu- dy Evaluation) study, which Provention initiated in the first quarter 2018. Top-line data is expected to be available in the second half of 2019."

P1 data • Immunology • Inflammation • Inflammatory Bowel Disease

TLR3 Blockade in Rhinovirus-Induced Experimental Asthma Exacerbations: A Randomized Controlled Study. (PubMed, J Allergy Clin Immunol) - "In summary, CNTO3157 was ineffective in attenuating the impact of HRV-16 challenge on lung function, asthma control, and symptoms in asthma, but suppressed cold symptoms in healthy subjects. Other approaches, including blockade of multiple pathways, or antiviral agents, need to be sought for this high unmet medical need."

Clinical • Journal

Provention Bio announces top-line results from its phase 1b PULSE clinical trial of PRV-300 in patients with moderate-to-severe ulcerative colitis (PRNewswire) - P2, N=37; PULSE (NCT03849599); "Provention Bio...announced preliminary top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 (toll-like receptor 3) monoclonal antibody, in patients with active, moderate-to-severe ulcerative colitis (UC)."

P1 data

Provention Bio reports fourth quarter and full year 2018 financial results and provides business update (PRNewswire) - P1, N=37; PULSE (NCT03849599); Sponsor: Provention Bio; "Top Line Data from Phase 1b Clinical Trial of PRV-300 (PULSE Study) in Moderate-to-Severe Ulcerative Colitis Expected in Q2."

P1 data

PULSE: A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P1b; N=37; Completed; Sponsor: Provention Bio, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

PULSE: A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P1b; N=37; Active, not recruiting; Sponsor: Provention Bio, Inc.

Clinical • New P1 trial